Coldstream Capital Management’s 10x Genomics TXG Stock Holding History
Bought
Maintained
Sold
Other funds holding TXG
AIM
NAMA
Coldstream Capital Management's TXG Position: Q2 2025 in Review
Coldstream Capital Management sold out of 10x Genomics (TXG) in Q2 2025, closing a stake of 2,745 shares — an estimated $24K sold.
Coldstream Capital Management first reported a position in TXG in Q1 2025 and held it in 1 quarter. The position peaked at $24K in Q1 2025. 297 funds tracked by Wall St. Rank hold TXG as of Q2 2025.
- Coldstream Capital Management reported no remaining 10x Genomics position as of Q2 2025 after selling out during the quarter.
- Coldstream Capital Management sold 2,745 10x Genomics shares in Q2 2025, an estimated $24K.
- Coldstream Capital Management first reported a position in 10x Genomics in Q1 2025 and held it in 1 quarter.
- Coldstream Capital Management's 10x Genomics position peaked at $24K in Q1 2025.
- 297 funds tracked by Wall St. Rank held 10x Genomics as of Q2 2025.
Based on Coldstream Capital Management's 13F filing for Q2 2025, filed 12 Aug 2025.